209 related articles for article (PubMed ID: 12947386)
41. The role of BRCA1 in homologous recombination repair in response to replication stress: significance in tumorigenesis and cancer therapy.
Zhang J
Cell Biosci; 2013 Feb; 3(1):11. PubMed ID: 23388117
[TBL] [Abstract][Full Text] [Related]
42. Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins.
Prakash R; Zhang Y; Feng W; Jasin M
Cold Spring Harb Perspect Biol; 2015 Apr; 7(4):a016600. PubMed ID: 25833843
[TBL] [Abstract][Full Text] [Related]
43. Homologous recombination in DNA repair and DNA damage tolerance.
Li X; Heyer WD
Cell Res; 2008 Jan; 18(1):99-113. PubMed ID: 18166982
[TBL] [Abstract][Full Text] [Related]
44. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.
Miki Y; Swensen J; Shattuck-Eidens D; Futreal PA; Harshman K; Tavtigian S; Liu Q; Cochran C; Bennett LM; Ding W
Science; 1994 Oct; 266(5182):66-71. PubMed ID: 7545954
[TBL] [Abstract][Full Text] [Related]
45. BRCA1 and BRCA2: different roles in a common pathway of genome protection.
Roy R; Chun J; Powell SN
Nat Rev Cancer; 2011 Dec; 12(1):68-78. PubMed ID: 22193408
[TBL] [Abstract][Full Text] [Related]
46. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
King MC; Marks JH; Mandell JB;
Science; 2003 Oct; 302(5645):643-6. PubMed ID: 14576434
[TBL] [Abstract][Full Text] [Related]
47. Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations.
Dedes KJ; Wilkerson PM; Wetterskog D; Weigelt B; Ashworth A; Reis-Filho JS
Cell Cycle; 2011 Apr; 10(8):1192-9. PubMed ID: 21487248
[TBL] [Abstract][Full Text] [Related]
48. Linkage of early-onset familial breast cancer to chromosome 17q21.
Hall JM; Lee MK; Newman B; Morrow JE; Anderson LA; Huey B; King MC
Science; 1990 Dec; 250(4988):1684-9. PubMed ID: 2270482
[TBL] [Abstract][Full Text] [Related]
49. The double-strand-break repair model for recombination.
Szostak JW; Orr-Weaver TL; Rothstein RJ; Stahl FW
Cell; 1983 May; 33(1):25-35. PubMed ID: 6380756
[TBL] [Abstract][Full Text] [Related]
50. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139.
Rogakou EP; Pilch DR; Orr AH; Ivanova VS; Bonner WM
J Biol Chem; 1998 Mar; 273(10):5858-68. PubMed ID: 9488723
[TBL] [Abstract][Full Text] [Related]
51. Facing the conundrum: which first-line therapy should be used for patients with metastatic triple-negative breast cancer carrying germline
Alaklabi S; Roy AM; Chaudhary LN; Gandhi S
Explor Target Antitumor Ther; 2023; 4(6):1301-1309. PubMed ID: 38213539
[TBL] [Abstract][Full Text] [Related]
52. iMUT-seq: high-resolution DSB-induced mutation profiling reveals prevalent homologous-recombination dependent mutagenesis.
Bader AS; Bushell M
Nat Commun; 2023 Dec; 14(1):8419. PubMed ID: 38110444
[TBL] [Abstract][Full Text] [Related]
53. Enhancement of Radiation Sensitivity by Cathepsin L Suppression in Colon Carcinoma Cells.
Abdelaziz RF; Hussein AM; Kotob MH; Weiss C; Chelminski K; Stojanovic T; Studenik CR; Aufy M
Int J Mol Sci; 2023 Dec; 24(23):. PubMed ID: 38069428
[TBL] [Abstract][Full Text] [Related]
54. Pathway-driven analysis of synthetic lethal interactions in cancer using perturbation screens.
Karimpour M; Totonchi M; Behmanesh M; Montazeri H
Life Sci Alliance; 2024 Jan; 7(1):. PubMed ID: 37863651
[TBL] [Abstract][Full Text] [Related]
55. BRCA1 and NORE1A Form a Her2/Ras Regulated Tumor Suppressor Complex Modulating Senescence.
Nelson N; Jigo R; Clark GJ
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627161
[TBL] [Abstract][Full Text] [Related]
56. A novel RBBP8(p.E281*) germline mutation is a predisposing mutation in familial hereditary cancer syndrome.
Yan J; Wu J; Wang Y; Di X; Jiang H; Wen D; Li D; Zhang S
J Mol Med (Berl); 2023 Oct; 101(10):1255-1265. PubMed ID: 37615686
[TBL] [Abstract][Full Text] [Related]
57. Multiomics analyses reveal
Zheng C; Wei Y; Zhang Q; Sun M; Wang Y; Hou J; Zhang P; Lv X; Su D; Jiang Y; Gumin J; Sahni N; Hu B; Wang W; Chen X; McGrail DJ; Zhang C; Huang S; Xu H; Chen J; Lang FF; Hu J; Chen Y
Sci Adv; 2023 Aug; 9(31):eadf3984. PubMed ID: 37540752
[TBL] [Abstract][Full Text] [Related]
58. Biallelic
Wineland D; Le AN; Hausler R; Kelly G; Barrett E; Desai H; Wubbenhorst B; Pluta J; Bastian P; Symecko H; D'Andrea K; Doucette A; Gabriel P; Reiss KA; Nayak A; Feldman M; Domchek SM; Nathanson KL; Maxwell KN; ;
JCO Precis Oncol; 2023 Aug; 7():e2300036. PubMed ID: 37535879
[TBL] [Abstract][Full Text] [Related]
59. Towards Personalized Management of Ovarian Cancer.
Algethami M; Kulkarni S; Sadiq MT; Tang HKC; Brownlie J; Jeyapalan JN; Mongan NP; Rakha EA; Madhusudan S
Cancer Manag Res; 2022; 14():3469-3483. PubMed ID: 36545222
[TBL] [Abstract][Full Text] [Related]
60. Discovery of synthetic lethal interactions from large-scale pan-cancer perturbation screens.
Srivatsa S; Montazeri H; Bianco G; Coto-Llerena M; Marinucci M; Ng CKY; Piscuoglio S; Beerenwinkel N
Nat Commun; 2022 Dec; 13(1):7748. PubMed ID: 36517508
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
